根治性前列腺切除术后生化复发患者首次18F-flotufolastat PET阴性后重复扫描的价值
该回顾性研究纳入101例根治性前列腺切除术后疑似生化复发且首次18F-flotufolastat PET阴性的患者,57%的重复扫描为阳性。PSA水平、PSA绝对/相对变化值、PSA速度和PSA倍增时间均影响检出率,ROC分析给出了各参数的统计最优切点。
要点
- 首次18F-flotufolastat PET阴性的生化复发患者中,重复扫描阳性率达57%。
- 重复扫描前PSA水平、PSA变化值、PSA速度和PSA倍增时间与扫描阳性显著相关。
- ROC分析提示PSA>0.82 ng/mL、绝对ΔPSA>0.50 ng/mL等切点可供临床参考。
核心结论
- 在根治性前列腺切除术后生化复发且首次18F-flotufolastat PET阴性的患者中,超过半数重复扫描可检出复发灶。
研究设计与样本
- 回顾性分析纳入2019至2024年间因疑似生化复发(PSA≥0.2 ng/mL)行第二次18F-flotufolastat PET且首次PET阴性的根治性前列腺切除术后患者,共101例,中位年龄70岁,中位PSA 0.79 ng/mL。
- 由两名委员会认证专家按miTNM分类判读18F-flotufolastat摄取病灶,并按重复扫描前PSA、PSA绝对/相对变化值、PSA速度和PSA倍增时间分层计算患者水平检出率,并行ROC曲线分析。
主要发现
- 101例患者中58例(57%)第二次18F-flotufolastat PET为阳性。
- 检出率随PSA水平、ΔPSA、PSA速度和PSA倍增时间变化而升高。
- 有无可疑18F-flotufolastat摄取两组间的PSA水平、ΔPSA、PSA速度和PSA倍增时间差异均有统计学意义(p<0.05)。
关键数值与推荐
- ROC分析得出的第二次PET阴性与阳性之间统计最优权衡切点为:PSA水平>0.82 ng/mL。
- ROC分析切点:绝对ΔPSA>0.50 ng/mL;相对ΔPSA>+100%。
- ROC分析切点:PSA速度>0.30 ng/mL/y;PSA倍增时间≤17个月。
临床怎么用
- 对于根治性前列腺切除术后生化复发且首次18F-flotufolastat PET阴性的患者,可考虑在PSA水平、PSA变化值、PSA速度或PSA倍增时间达到上述切点时重复扫描。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the potential of a second 18F-flotufolastat positron emission tomography (PET) scan in patients with suspected biochemical recurrence (BCR) of prostate cancer (PCa) who had a previous negative 18F-flotufolastat PET, and to identify prostate-specific antigen (PSA) parameters influencing detection efficacy. METHODS: Our retrospective analysis included data from patients who underwent second 18F-flotufolastat PET between 2019 and 2024, following negative 18F-flotufolastat PET for suspected BCR of PCa (PSA ≥ 0.2 ng/mL) after radical prostatectomy. Two board-certified experts classified 18F-flotufolastat-avid lesions per miTNM categories. Patient-level detection rates were stratified by: pre-PET scan PSA; absolute/relative difference in PSA (ΔPSA) between negative first and second PET; PSA velocity (PSAvel); PSA doubling time (PSAdt). Receiver operating characteristic (ROC) curve analyses were performed. RESULTS: Of 101 patients (median age = 70 years; median PSA = 0.79 ng/mL), 58 (57%) had a positive second 18F-flotufolastat scan. Detection rates increased with PSA level, ΔPSA, PSAvel, and PSAdt. Differences in PSA level, ΔPSA, PSAvel, and PSAdt between groups with/without suspicious 18F-flotufolastat uptake were statistically significant (p < 0.05). Cut-offs for statistically optimal trade-off between negative and positive second PET (ROC analyses) were: PSA level > 0.82 ng/mL; absolute ΔPSA > 0.50 ng/mL; relative ΔPSA > + 100%; PSAvel > 0.30 ng/mL/y; PSAdt ≤ 17 months. CONCLUSION: In over half of patients presenting with BCR after radical prostatectomy and an initial negative 18F-flotufolastat PET, second 18F-flotufolastat PET identified recurrent lesions. PSA level at time of second PET, absolute/relative ΔPSA, PSAvel, and PSAdt influenced scan positivity.
引用
- Kirchhoff S, Lederer A, Lorenzini T, et al. Value of a repeat 18F-flotufolastat PET scan following a negative scan in patients with suspected biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2026. PMID: 41721835. doi:10.1007/s00259-026-07786-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。